Literature DB >> 10336913

Randomised comparison of electrode positions for cardioversion of atrial fibrillation.

T P Mathew1, A Moore, M McIntyre, M T Harbinson, N P Campbell, A A Adgey, G W Dalzell.   

Abstract

OBJECTIVE: To compare the relative efficacy of anteroanterior v anteroposterior electrode pad positions for external cardioversion of atrial fibrillation.
DESIGN: Prospective randomised trial.
SETTING: Tertiary referral cardiology centre in the United Kingdom. PATIENTS: 90 patients undergoing elective cardioversion for atrial fibrillation.
INTERVENTIONS: Cardioversion was attempted with self adhesive electrode pads with an area of 106 cm2 placed either in the anteroanterior (AA) or anteroposterior (AP) positions. Initial shock was 100 J which, if unsuccessful, was followed by 200 J, 300 J, and 360 J if required. Peak current and transthoracic impedance were measured. MAIN OUTCOME MEASURES: Cardioversion success rate and energy requirements.
RESULTS: Cardioversion was successful in 81% of the patients (73/90). There was no statistically significant difference in the cardioversion success rate (AA 84%, 38/45 patients; AP 78%, 35/45 patients; p = 0.42) or mean (SD) energy requirement for all patients (AA 223 (96.1) J; AP 232 (110) J) or for patients who were successfully cardioverted (AA 197.9 (82.4) J; AP 195.4 (97.2) J; p = 0.9) between the two pad positions. The mean transthoracic impedance (TTI) for the first shock (AA 77.5 (18.4) ohms; AP 73.7 (18.7) ohms; p = 0.34) was not significantly different between the two groups. TTI correlated significantly with body mass index, percentage body fat, and chest AP diameter. There was a progressive decrease in TTI with serial shocks. While aetiology and TTI were the two independent significant predictive factors for energy requirement, duration of atrial fibrillation was the only independent predictor of cardioversion success in a multivariate analysis.
CONCLUSIONS: Electrode pad position is not a determinant of cardioversion success rate or energy requirement.

Entities:  

Mesh:

Year:  1999        PMID: 10336913      PMCID: PMC1729050          DOI: 10.1136/hrt.81.6.576

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  25 in total

1.  Transthoracic defibrillation: effect of sternotomy on chest impedance.

Authors:  R E Kerber; S Vance; S J Schomer; D J Mariano; F Charbonnier
Journal:  J Am Coll Cardiol       Date:  1992-07       Impact factor: 24.094

2.  Transthoracic impedance to direct current discharge: effect of repeated countershocks.

Authors:  C F Dahl; G A Ewy; M D Ewy; E D Thomas
Journal:  Med Instrum       Date:  1976 May-Jun

3.  Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter.

Authors:  I C Van Gelder; H J Crijns; W H Van Gilst; R Verwer; K I Lie
Journal:  Am J Cardiol       Date:  1991-07-01       Impact factor: 2.778

4.  Electroversion of lone atrial fibrillation and flutter including haemodynamic studies at rest and on exercise.

Authors:  L Resnekov; L McDonald
Journal:  Br Heart J       Date:  1971-05

5.  Defibrillator electrode-chest wall coupling agents: influence on transthoracic impedance and shock success.

Authors:  P E Aylward; R Kieso; P Hite; F Charbonnier; R E Kerber
Journal:  J Am Coll Cardiol       Date:  1985-09       Impact factor: 24.094

6.  Energy, current, and success in defibrillation and cardioversion: clinical studies using an automated impedance-based method of energy adjustment.

Authors:  R E Kerber; J B Martins; M G Kienzle; L Constantin; B Olshansky; R Hopson; F Charbonnier
Journal:  Circulation       Date:  1988-05       Impact factor: 29.690

7.  Elective cardioversion: influence of paddle-electrode location and size on success rates and energy requirements.

Authors:  R E Kerber; S R Jensen; J Grayzel; J Kennedy; R Hoyt
Journal:  N Engl J Med       Date:  1981-09-17       Impact factor: 91.245

8.  Advance prediction of transthoracic impedance in human defibrillation and cardioversion: importance of impedance in determining the success of low-energy shocks.

Authors:  R E Kerber; C Kouba; J Martins; K Kelly; R Low; R Hoyt; D Ferguson; L Bailey; P Bennett; F Charbonnier
Journal:  Circulation       Date:  1984-08       Impact factor: 29.690

9.  Effects of electrophysiologic studies resulting in electrical countershock or burst pacing on left ventricular systolic and diastolic function.

Authors:  M F Stoddard; A J Labovitz; L L Stevens; T A Buckingham; R R Redd; H L Kennedy
Journal:  Am Heart J       Date:  1988-08       Impact factor: 4.749

10.  Transthoracic resistance in human defibrillation. Influence of body weight, chest size, serial shocks, paddle size and paddle contact pressure.

Authors:  R E Kerber; J Grayzel; R Hoyt; M Marcus; J Kennedy
Journal:  Circulation       Date:  1981-03       Impact factor: 29.690

View more
  5 in total

Review 1.  Theory and practice of defibrillation: (1) Atrial fibrillation and DC conversion.

Authors:  A A J Adgey; S J Walsh
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

2.  Cardioversion: past, present, and future.

Authors:  Ivan Cakulev; Igor R Efimov; Albert L Waldo
Journal:  Circulation       Date:  2009-10-20       Impact factor: 29.690

3.  Esophageal electric fields are predictive of atrial cardioversion success-a finite element analysis.

Authors:  David A Fitch; Amy L de Jongh Curry
Journal:  Ann Transl Med       Date:  2015-08

Review 4.  A Systematic Review of the Transthoracic Impedance during Cardiac Defibrillation.

Authors:  Yasmine Heyer; Daniela Baumgartner; Christian Baumgartner
Journal:  Sensors (Basel)       Date:  2022-04-06       Impact factor: 3.576

Review 5.  [Adult advanced life support].

Authors:  Jasmeet Soar; Bernd W Böttiger; Pierre Carli; Keith Couper; Charles D Deakin; Therese Djärv; Carsten Lott; Theresa Olasveengen; Peter Paal; Tommaso Pellis; Gavin D Perkins; Claudio Sandroni; Jerry P Nolan
Journal:  Notf Rett Med       Date:  2021-06-08       Impact factor: 0.826

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.